AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01861574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TMS 45 min
Description: Real TMS 45 minutes after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
Study NCT01861574 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Real TMS 45 min
Description: Real TMS 45 minutes after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
Study NCT01861574 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS 45 min
Description: Sham TMS 45 minutes after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
Study NCT01861574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real TMS 4 Hours
Description: Real TMS 4 hours after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
Study NCT01861574 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Real TMS 4 Hours
Description: Real TMS 4 hours after surgery, first determined resting motor threshold (rMT) by starting with 40% of the machine output and 0.5 Hz stimulus frequency. The coil was positioned over the motor cortex and then adjusted until each pulse results in movement of the right thumb. The machine output was then adjusted to the lowest intensity that reliably produces thumb movement. Parameter estimation by sequential testing was used to determine the amount of machine energy necessary to visibly move the thumb 50% of the time. rMT was assessed before each rTMS treatment. The left prefrontal cortex was the cortical target for rTMS treatment. The EEG-10-20 system was used to locate the prefrontal cortex (F3).
Study NCT01861574 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS 4 Hours
Description: Sham TMS 4 hours after surgery used specifically designed rTMS coil that produces auditory signals identical to real (active) TMS coils but is shielded so that actual stimulation does not occur. The eSham system was used to mimic sensations of real rTMS. This system produces mild tingling on the scalp underneath the sham rTMS coil, making it difficult in differentiating between real and sham. The amount of electrical stimulation necessary to match real rTMS pulses was determined using an algorithm (parameter estimation by sequential testing). All subjects underwent the sham titration at the beginning of every rTMS session regardless of group assignment. The left prefrontal cortex was the cortical target for rTMS treatment, located using the EEG-10-20 system.
Study NCT03328143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lavender (Lavandula angustifolia)
Description: Lavender (Lavandula angustifolia) is an essential oil.
Study NCT03610737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MILD Procedure
Description: The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.~Other Name: MILD lumbar decompression
Study NCT03610737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management (CMM)
Description: CMM can include physical therapy, home exercise, pain medication, epidural steroid injections, nerve blocks, and other lumbar steroid injections.
Study NCT03659253 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Fluid Based Self Testing
Description: The intervention will introduce provider supervised and unsupervised self-testing as an option for early HIV diagnosis among MSM community in Denpasar Bali Indonesia.
Study NCT00650117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)
Description: single application
Study NCT00650117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)
Description: single application
Study NCT00650117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duragesic 25 mcg/h + Microfoam Tape (3M)
Description: single application
Study NCT04764370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WeFlow-Ach Moduler Embedded Branch Stent Graft System
Description: The modular embedded aortic arch stent graft system consists of the embedded ascending aorta stent graft system, the arch aorta stent graft system and the branch stent system.
Study NCT03659253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simplified ART Initiation
Description: In this intervention, there will be a change in the clinical practice of ART initiation. In the current practice, clients are asked to perform full pre-ART laboratory examination (complete blood count, liver and renal function tests) before decision of ART initiation. In this intervention, the study participants who are already confirmed as HIV positive and meet specific clinical criteria (see below) will initiate ART (antiretroviral therapy) immediately (after clients' approval) without having to perform full pre-ART laboratory examination. Here, laboratory criteria for initiating ART will be simplified and specific laboratory examination, I.e. creatinine test will be delayed in two weeks after ART initiation.
Study NCT01254318 — intervention group
Intervention type: OTHER
Intervention: Standard Care
Description: Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.
Study NCT03659253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBO AND BROTHEL-BASED ART SERVICE
Description: The CBOs involved in this intervention are Kebaya and Vesta. Kebaya is an CBO working for Transgender (TG) community. It serves as community gathering place for TG and others, as HIV testing site on regular bases, and also as shelter for homeless HIV patients. The proposed intervention Is that HATI Project will provide HIV testing and treatment in the community, CBO and brothel in collaboration with nearby Puskesmas.
Study NCT03659253 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS REMINDER
Description: HATI SMS reminder: short message services as reminders to inform ART patients when to take medication, visit the clinics (1 week before the next visit) and remind if they miss clinic appointment.
Study NCT03659253 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MOTIVATIONAL INTERVIEWING
Description: The approach used in this intervention is an individual counselling with a MI approach, as it is considered a brief form of therapy have been known to be effective in improving HIV treatment adherence.~The sessions will be held from 3 to up to 10 MI counselling over 6-month period of intervention. The goal of this intervention is to help PWID gain an understanding of their medication-taking behaviors and the actions necessary to successfully maintain a high level of adherence
Study NCT02177539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclopentolate
Description: Traditional scheme. Cyclopentolate, repeat dosage 5 minutes and then wait 40 minutes to retinoscopy. Total wait 45 minutes.
Study NCT02177539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclopentolate
Description: Traditional scheme. Cyclopentolate, repeat dosage 5 minutes and then wait 40 minutes to retinoscopy. Total wait 45 minutes.
Study NCT02177539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclopentolate+tropicamide+phenylephrine
Description: New scheme. All drugs together and wait 30 minutes for retinoscopy
Study NCT02177539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclopentolate+tropicamide+phenylephrine
Description: New scheme. All drugs together and wait 30 minutes for retinoscopy
Study NCT00861614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: 5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
Study NCT00861614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
Study NCT03963661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: c-SIGHT (computorized spatial innatention grasping home-based therapy)
Description: C-SIGHT will be self-administered at people's homes. c-SIGHT is a computerized therapy administered via people's television. The therapy involves performing repeated rod lifts with the less impaired arm in response to auditory and visual instructions presented on the television screen connected to a laptop. A small motion-tracking camera monitors rod lifts during therapy sessions. People will be asked to self-administer c-SIGHT for 1 hour a day (30min after breakfast and 30min after lunch) for 7 consecutive days. The first day of therapy will be performed with a therapist there for training purposes.
Study NCT02687321 — intervention group
Intervention type: OTHER
Intervention: Determination of CA 125 and HE4, Computed tomography
Description: Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
Study NCT00685321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H1 deep TMS coil
Description: 20 daily deep rTMS treatment
Study NCT00685321 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: inactive treatment
Study NCT00944658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apremilast
Description: 10mg twice a day, dose was titrated by 20mg every 2 days until the maximum dose 30mg twice a day for 12weeks
Study NCT00944658 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Description: twice a day
Study NCT02452684 — intervention group
Intervention type: DRUG
Intervention: Eszopiclone
Description: The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
Study NCT01788345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non- invasive ventilation
Description: non-invasive bi-level ventilation with IPAP and EPAP.
Study NCT03554993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-99677
Description: CC-99677
Study NCT03554993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03221010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational Interview (MI) is a person-centered, communicative method whose purpose is to work and increase the user's motivation for behavior change.
Study NCT03221010 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional cognitive-behavioral approach
Description: This approach aims to combine cognitive interventions in the training of behavioral skills in patients, developing strategies to cope with the problem and detecting situations of risk, mobilizing the subject for his own process of change. Helps correct cognitive dysfunctions and behavioral changes in specific situations.
Study NCT03221010 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional cognitive-behavioral approach
Description: This approach aims to combine cognitive interventions in the training of behavioral skills in patients, developing strategies to cope with the problem and detecting situations of risk, mobilizing the subject for his own process of change. Helps correct cognitive dysfunctions and behavioral changes in specific situations.
Study NCT02111785 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: Treatment with a short course of oral dexamethasone
Study NCT02111785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Treatment with a short course of oral dexamethasone
Study NCT00764374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM443
Description: oral
Study NCT04354766 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: This study will require a blood sample (4 ACD tubes, 20 ml) at one time.
Study NCT01789996 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alternative six minute walk test
Description: Alternate instructions will be given Subjects will~1. walk as fast as they can in 6 minutes~2. walk as normally as they can in 6 minutes~3. walk leisurely as they can in 6 minutes. Pts will serve as their own controls.
Study NCT01789996 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard six minute walk test
Description: Subjects will walk as far as they can in 6 minutes
Study NCT00199498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apical RV lead placement
Description: RV lead implanted ( according to randomization )at the apex
Study NCT00199498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Septal RV lead placement
Description: RV lead is implanted (according to randomization), on septum
Study NCT00750100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human chorionic gonadotropin
Description: hCG 200IU in the late follicular phase
Study NCT00750100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant gonadotropins
Description: 200 IU per day during controlled ovarian stimulation
Study NCT02235467 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ABA parent training
Description: A parent training based on Applied Behavior Analysis that is going to be delivered by video modeling in 21 weeks
Study NCT02357290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Treatment with N-Acetylcysteine
Study NCT04243460 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Xenogeneic collagen matrix (XCM) graft augmentation
Description: 12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate TKT at two points using ultrasound equipment (Pirop®, Echoson).~Intraoral radiographs were taken using a paralleling technique with a Rinn-type film holder in high resolution mode (Visualixe HD®, Gendex®, USA). Two images of each region were selected to calculate the marginal bone changes:
Study NCT04243460 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Connective tissue graft augmentation (CTG)
Description: 12 months after gingival augmentation Measurement of marginal bone level and soft tissue thickness were done. STT (soft tissue thickness) was measured using ultrasonography with a Pirop® dental, ultrasound device (Echoson Company, Poland). The patients underwent a clinical and ultrasound examination before, 3 and 12 months after gingival augmentation (GA) respectively to evaluate STT (soft tissue thickness) at two points using ultrasound equipment (Pirop®, Echoson).
Study NCT02254408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Presatovir
Description: Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
Study NCT02254408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally or via nasogastric tube
Study NCT03766841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Enrollment
Description: Research coordinator will assist patients in account creation and usage of the tool.
Study NCT02176044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside infusion
Study NCT02176044 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02410967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
Study NCT02410967 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Attention Task
Description: At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
Study NCT03202472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implanted Medical Device
Description: Radiofrequency tag
Study NCT03202472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mammography
Description: Undergo mammogram for image-guided placement of radiofrequency tag
Study NCT03202472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03202472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RFID) -Guided Localization
Description: Undergo radiofrequency-guided localization
Study NCT03202472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Undergo ultrasound for image-guided placement of radiofrequency tag
Study NCT01057030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsules, Oral, 125 mg, once daily, 14 days
Study NCT01057030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 14 days
Study NCT03815084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pd-1 and DC-NK cells
Description: total dose of 10ml KEYTRUDA® (pembrolizumab) will be administered at day0, 60million DC cells and 3 billion NK at day1, 3 billion NK cells at day2, 3 billion NK cells at day3 .
Study NCT03040882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cotton sock
Description: Application of a cotton sock in the immediate postoperative period before applied the Walker
Study NCT03040882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Elastic Compression Wraps
Description: Application of an Elastic Compression Wraps in the lower limb in the immediate postoperative period before applied the Walker (standard care)
Study NCT00487734 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Testosterone gel
Description: testosterone gel, applied daily. Dosed to achieve testosterone level \<500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.
Study NCT00487734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for testosterone gel
Description: Placebo gel, 2.5g for each gel packet